Alliance Pharma Share Discussion Threads

[baldrick1] 07/6/2024 11:40

Shouldn't it be torching time? ;)))

[baldrick1] 07/6/2024 11:38

I'm in BH;)))

[blackhorse23] 07/6/2024 11:28

I got email reply & spoke to investor relations, accounting delays due to current stock accounting & valuations , but last year number is correct as mentioned in 29th January. Account is ready , once signed off by CEO it will be published & they are aware has to publish before end of the month. So ALL GOOD FOR ME

[baldrick1] 07/6/2024 10:58

I'm out with the ne donkeys ;))

[baldrick1] 07/6/2024 10:07

And in with the same new donkeys ;))

[baldrick1] 07/6/2024 10:06

I'm out with the new donkeys;))

[tomzimerman] 07/6/2024 09:40

Last top up for the donkey below lol

[blackhorse23] 07/6/2024 09:22

WIN WIN BUY

[baldrick1] 07/6/2024 09:12

I'm in ;)))

[baldrick1] 07/6/2024 08:32

FOMO mode:)

[seagreen] 07/6/2024 08:17

fatfish I was referencing other people's thoughts if you look higher up not mine I concur Deloittes will not be responsible etc

re
"mmmmmmm don't quite know what you're referring to, can't imagine deloittes will be responsible for anything, unless they fraudulently fudge the figures"

[baldrick1] 07/6/2024 07:33

Traders are seeing very good value at this level again, and the buying starts :)

[blackhorse23] 07/6/2024 07:29

Results will be as below plus add 8m from court winning: Financial summaryThe Group delivered record see-through1 revenues in the Period of £182.7m (FY22: £172.0m), up 6% versus the prior period and up 7% at constant exchange rates ("CER"). Excluding sales from ScarAway and the US rights to Kelo-Cote in Q1 23, both acquired in March 2022 (the "US Acquisition"), like-for-like see-through revenues increased 6% CER. Continued strong consumer demand, particularly in China, drove significant recovery in Kelo-Cote franchise revenues in H2, leading to FY23 revenues of £63.2m, up 29% CER (FY22: £50.0m). Nizoral revenues increased 3% CER to £21.7m (FY22: £21.8m) whilst Amberen revenues declined 6% CER on an underlying basis (excluding the leading discount store account that was lost in 2022) and decreased 25% CER to £11.2m (FY22: £14.9m) on a reported basis. With Other Consumer brands up 5% CER to £40.3m (FY22: £38.4m), total see-through Consumer Healthcare revenues increased 11% CER to £136.4m. Prescription Medicine revenues were stable at £46.3m (FY22: £46.8m), reflecting a strong recovery in H2 as expected, as previously out of stock products became available. Underlying profit for the Period is anticipated to be in-line with market expectations. Cash and debtFree cash flow in the Period rose 34% to £21.1m (FY22: £15.8m) and net debt reduction continued, falling to £92.4m at 31 December 2023 (31 December 2022: £102.0m). Group leverage2 (as at 31 December 2023) is expected to be significantly below that at 30 June 2023 (2.7x), and in-line with previous guidance.OutlookDemand for the Group's brands remains strong. Alliance's clear focus on the core Consumer Healthcare business, in addition to our well-established, scalable platform across EMEA, APAC and the US, is expected to deliver continued strong organic growth over the medium term. In 2024, the Board anticipates our Consumer Healthcare revenues to continue to grow above that of the broader Consumer Healthcare market, with stable Prescription Medicine revenues.In order to achieve our medium-term objectives, in 2024, the Board anticipates increased investment in sales and marketing, both directly and through the Group's distributors. The Company will also continue to deliver innovation in 2024 to further expand the reach of its brands. As a result, the Board anticipates that profits in 2024 will be in-line with 2023.

[baldrick1] 07/6/2024 07:25

Interest rates could start to come down next month, imho

[baldrick1] 07/6/2024 07:23

Results will be next week after the fat mouth has spoken ;))

[fatfish] 07/6/2024 07:16

seagreen

Time is till end of JUNE but accounting firm will be liable of any issues not company

mmmmmmm don't quite know what you're referring to, can't imagine deloittes will be responsible for anything, unless they fraudulently fudge the figures

[denholm elliott] 07/6/2024 06:12

Single digit share price likely coming here. I'd salvage whatever you can before the drop.

[maverick67] 07/6/2024 03:55

He will always appear on the risers boards and say taken profit to APH he's a desperate man very much under the water.. he was the same with Curry's

[seagreen] 07/6/2024 00:44

Atomatic suspension looms unless they pull their fingers out

tyranosaurus
6 Jun '24 - 17:45 - 2904 of 2908
0 0 0
Listed companies must file within 6 months of their accounting reference date.
Let`s hope those Deloitte fellows know that.
Blackhorse23
6 Jun '24 - 17:49 - 2905 of 2908
0 0 0
Time is till end of JUNE but accounting firm will be liable of any issues not company

[wad collector] 06/6/2024 21:39

He also posted on the Unilever site that he added APH again today. So , Blackhorse, answer the question, why are you making these claims on other BBs? How come you make multiple claims to selling those companies despite never claiming to have bought them previously?